Tetsuji Takayama
Research Subjects
Tetsuji Takayama has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
Koichi Okamoto
Tokushima Daigaku Igakubu Daigakuin Ikgaku Kyoikubu
18 shared publications- Naoki Muguruma
Department of Gastroenterology and Oncology Tokushima University Graduate School of Biomedical Sciences Tokushima Japan
18 shared publications Tetsuo Kimura
16 shared publications- Toshiya Okahisa
Department of Gastroenterology and Oncology, The University of Tokushima Graduate School, Tokushima, Japan
15 shared publications - Hiroshi Miyamoto
Department of Gastroenterology and Oncology, Tokushima University Graduate School of Medical Science, Tokushima 770-8503, Japan
13 shared publications Shinji Kitamura
11 shared publications
Latest Publications
- Open Access
Therapeutic Efficacy and Safety of Lenvatinib for Unresectable Hepatocellular Carcinoma Beyond Progression with Sorafenib
Background ? Aims The efficacy and safety of lenvatinib ( LEN ) as a second/third-line treatment for unresectable hepatocellular carcinoma (HCC) after sorafenib (SOR) therapy remains unknown. We evaluated the outcomes of second/third-line treatment of LEN, investigated the sensitivity of SOR-resistant HCC cell line (PLC/PRF5-R2) to LEN, and their signal transduction pathway by protein array analysis. Methods We retrospectively enrolled 57 unresectable HCC patients. Radiologic responses in 53 patients were evaluated by modified Response Evaluation Criteria in Solid Tumors. Active signal transduction pathways in cells were identified by protein array analysis, including 1205 proteins. Results Patients comprised 34 tyrosine kinase inhibitor (TKI)-naive (first-line), nine SOR-intolerant (second-line), and ten resistant to regorafenib (third-line). Objective response rates (ORRs) were 61.8% (21/34) in TKI-naive, 33.3% (3/9) in second-line, and 20.0% (2/10) in third-line groups. The overall survival (OS) and the progression free survival (PFS) in the first-line was significantly longer than those in third-line group ( p <0.05). Patients with better liver functional reserve (Child score, ALBI grade) exhibited higher ORR and longer OS. LEN was well-tolerated as second/third-line treatment. The IC 50 value of LEN against PLC/PRF5-R2 cells (30 μM) was significantly higher than that against PLC/PRF5 cells (6.4 μM). LEN inhibited significantly more signal transduction pathways related to FRS2, a crucial FGFR downstream molecule, in PLC/PRF5 than PLC/PRF5-R2 cells. Conclusions LEN was active and safe as a second/third-line treatment for unresectable HCC. LEN seems to be more effective for HCC patients with better hepatic reserve function or before TKI-resistance is acquired because of partial cross-resistance to SOR.
Open AccessTherapeutic Efficacy and Safety of Lenvatinib for Unresectable Hepatocellular Carcinoma Beyond Progression with Sorafenib
Background ? Aims The efficacy and safety of lenvatinib ( LEN ) as a second/third-line treatment for unresectable hepatocellular carcinoma (HCC) after sorafenib (SOR) therapy remains unknown. We evaluated the outcomes of second/third-line treatment of LEN, investigated the sensitivity of SOR-resistant HCC cell line (PLC/PRF5-R2) to LEN, and their signal transduction pathway by protein array analysis. Methods We retrospectively enrolled 57 unresectable HCC patients. Radiologic responses in 53 patients were evaluated by modified Response Evaluation Criteria in Solid Tumors. Active signal transduction pathways in cells were identified by protein array analysis, including 1205 proteins. Results Patients comprised 34 tyrosine kinase inhibitor (TKI)-naive (first-line), nine SOR-intolerant (second-line), and ten resistant to regorafenib (third-line). Objective response rates (ORRs) were 61.8% (21/34) in TKI-naive, 33.3% (3/9) in second-line, and 20.0% (2/10) in third-line groups. The overall survival (OS) and the progression free survival (PFS) in the first-line was significantly longer than those in third-line group ( p <0.05). Patients with better liver functional reserve (Child score, ALBI grade) exhibited higher ORR and longer OS. LEN was well-tolerated as second/third-line treatment. The IC 50 value of LEN against PLC/PRF5-R2 cells (30 μM) was significantly higher than that against PLC/PRF5 cells (6.4 μM). LEN inhibited significantly more signal transduction pathways related to FRS2, a crucial FGFR downstream molecule, in PLC/PRF5 than PLC/PRF5-R2 cells. Conclusions LEN was active and safe as a second/third-line treatment for unresectable HCC. LEN seems to be more effective for HCC patients with better hepatic reserve function or before TKI-resistance is acquired because of partial cross-resistance to SOR.
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Sa1209 - Clinicopathological Analyses of Colorectal Polyps and Cancers in Serrated Polyposis Syndrome
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Sa1209 - Clinicopathological Analyses of Colorectal Polyps and Cancers in Serrated Polyposis Syndrome
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S44
Optical Molecular Imaging of Aberrant Crypt Foci in the Human Colon by Glutathione S-Transferase-Activated Fluorogenic Probe
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S44
Optical Molecular Imaging of Aberrant Crypt Foci in the Human Colon by Glutathione S-Transferase-Activated Fluorogenic Probe
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S44
A New Theranostic Combination of Fluorescent Molecular Imaging and Laser Therapy Targeting C-Kit in Gastrointestinal Stromal Tumors
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S44
A New Theranostic Combination of Fluorescent Molecular Imaging and Laser Therapy Targeting C-Kit in Gastrointestinal Stromal Tumors
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S434
Sa2031 Molecular Imaging Targeting Epidermal Growth Factor Receptor in Detection and Evaluation of Therapeutic Efficacy for Colorectal Cancer
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S434
Sa2031 Molecular Imaging Targeting Epidermal Growth Factor Receptor in Detection and Evaluation of Therapeutic Efficacy for Colorectal Cancer
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S514
Su1468 MRP3 As a Novel Resistance Factor for Sorafenib in Hepatocellular Carcinoma
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S514
Su1468 MRP3 As a Novel Resistance Factor for Sorafenib in Hepatocellular Carcinoma
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S517-S518
Su1483 Des-g-carboxy Prothrombin (DCP) Is Produced by Overexpression of Prothrombin Gene in Hepatocellular Carcinoma
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S517-S518
Su1483 Des-g-carboxy Prothrombin (DCP) Is Produced by Overexpression of Prothrombin Gene in Hepatocellular Carcinoma
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S716-S717
Mo1533 Influence of Lifestyle and Lifestyle-Related Disease on Nonalcoholic Fatty Liver Disease in Japanese With Metabolic Syndrome
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S716-S717
Mo1533 Influence of Lifestyle and Lifestyle-Related Disease on Nonalcoholic Fatty Liver Disease in Japanese With Metabolic Syndrome
- 1 February 2015
- p. 365-8
[Constipation and ileus].